Nadia Harbeck, MD, PhD, discusses the background of the phase 2 WSG ADAPT-TP trial in hormone receptor-positive, HER2-positive early-stage breast cancer.
Nadia Harbeck, MD, PhD, head, Breast Center, chair, Conservative Oncology, Department of Obstetrics and Gynaecology, University of Munich, discusses the background of the phase 2 WSG ADAPT-TP trial (NCT01779206) in hormone receptor (HR)-positive, HER2-positive early-stage breast cancer.
Findings from the WSG ADAPT-TP trial were presented during the 2021 ESMO Congress, examining the predictive impact of biomarkers on survival after de-escalated neoadjuvant ado-trastuzumab emtansine (T-DM1; Kadcyla) with or without endocrine therapy vs trastuzumab (Herceptin) plus endocrine therapy in 372 patients with HR-positive, HER2-positive early-stage breast cancer, Harbeck explains.
In previous years, the pathologic complete response (pCR) rate resultsshowed a 41% pCR rate after only 4 cycles of T-DM1, Harbeck says. The pCR rates were similar irrespective of whether endocrine therapy was added to TDM-1. Moreover, the control arm reported a 15% pCR rate with trastuzumab plus endocrine therapy, Harbeck concludes.